1、Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. Int J Clin Oncol. 2022 Feb;27(2):332-339. 2、Junji Tsurutani, et al. Subgroup Analysis of Patients ...
[6]Tan, R. S. Y. C. et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: An international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 20, 1–15 (2022). [7]Li, Y. et al. In real life, low-level HER2 expr...
HER2-low乳腺癌在不同分子亚型中的特征方面:在Luminal型乳腺癌中,PIK3CB、ACVR18、HGF和ERG是HER2-low亚组与HER2-0亚组之间突变频率显著不同的关键基因(见图2b);在三阴性乳腺癌(TNBC)中,HER2-low亚组与HER2-0亚组之间突变频率差异显著的主要基因为FGFR3、ATRX和IGF1R(见图2c)。值得注意的是,所有在TNBC中...
[2]Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al.. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised,...
3. Modi S, Jacot W, Iwata H, et al. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study[J]....
参考来源: https://www.targetedonc.com/view/fda-approves-trastuzumab-deruxtecan-in-her2-low-metastatic-breast-cancer haoeyou.com/zhongliu_aizheng/ruxianai/20220812/7192.html 「文中图片来源Pixabay,均已获版权方授权」
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients(pts) with hormone receptor-positive (HR+), human epidermal growth factorreceptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) withprior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)....
2.Aleix Prat,et al.Determination of HER2-Low Status in Tumors of Patients With Untesectable and/or Metastatic Breast Cancer.2022 SABCS:HER2-18. 3.Giuseppe Viale,et al.Retrospective study to estimate the prevalence of HER2-low breast cancer(BC)and describe its clinicopathological characteristics.20...
Cancer. 2023 Nov 7. IF: 6.2 HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis. Lin M, Luo T, Jin Y, Zhong X, Zheng D, Zeng C, Guo Q, Wu J, Shao ZM, Hu X, Yang W, Zhang J. ...
[7] Denkert C, Lebeau A, Schildhaus HU, Jackisch C, Rüschoff J. New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis. Pathologie (Heidelb). 2023 Nov;44(Suppl 2):53-60. doi: 10.1007/s00292-022-01139-4. Epub 2022 Dec 6. PMID: 36...